denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: JOINT Session - The Lymphoma Microenvironment and Its Impact on Therapy
Hematology Disease Topics & Pathways:
Research, Biological therapies, Lymphomas, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies
Disclosures: Locke: CERo Therapeutics: Research Funding; Imedex: Other: Education or editorial activity; Society for Immunotherapy of Cancer: Other: Education or editorial activity; ), National Cancer Institute: Research Funding; Leukemia and Lymphoma Society: Research Funding; Clinical Care Options Oncology: Other: Education or editorial activity; CAREducation: Other: Education or editorial activity; BioPharm Communications: Other: Education or editorial activity; Aptitude Health: Other: Education or editorial activity; ASH: Other: Education or editorial activity; Takeda: Consultancy; Sana: Consultancy; Daiichi Sankyo: Consultancy; BMS: Research Funding; A2: Consultancy; Celgene: Consultancy; Other: Patents & Royalties: patents, royalties, other intellectual property from several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy.; Wugen: Consultancy; Umoja: Consultancy; Novartis: Consultancy, Research Funding; Legend Biotech: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Janssen: Consultancy; Iovance: Consultancy; GammaDelta Therapeutics: Consultancy; Emerging Therapy Solutions Gerson Lehrman Group: Consultancy; EcoR1: Consultancy; Cowen: Consultancy; Calibr: Consultancy; Cellular Biomedicine Group: Consultancy; Bristol Myers Squibb/Celgene: Consultancy; Bluebird Bio: Consultancy, Research Funding; Allogene: Consultancy, Research Funding; Amgen: Consultancy.
See more of: Scientific Program